CBMG: FDA Designations for Cell Therapy to Treat DLBCL

CBMG: FDA Designations for Cell Therapy to Treat DLBCL

The U.S. Food and Drug Administration (FDA) has granted both a Fast Track Designation and a Regenerative Medicine Advanced Therapy Designation (RMAT) to Cellular Biomedicine’s (CBMG) autologous b-specific therapy, C-CAR039, for the treatment of patients with diffuse...
Anivive Awarded FDA Grant for Canine Cancer Research

Anivive Awarded FDA Grant for Canine Cancer Research

The U.S. Food and Drug Administration (FDA) has awarded Anivive, a pet health tech company, a $500,000 USD grant to continue research on  LAVERDIA™ -CA1 (verdinexor) and its effect on treating canine cancer. As one of four companies selected for the MUMS grant,...
B-Cell Lymphoma Drug Receives FDA Priority Review

B-Cell Lymphoma Drug Receives FDA Priority Review

ADC Therapeutic’s Biologics License was approved by the U.S. Food and Drug Administration (FDA) for their relapsed/refractory diffuse large B-cell Lymphoma drug candidate. The antibody conjugate drug, that catalyzes cancer cell death is being investigated in a...